Literature DB >> 17987400

De novo nephrotic syndrome following pegylated interferon alfa 2b/ribavirin therapy for chronic hepatitis C infection.

Jose L Tovar1, Maria Buti, Alfonso Segarra, Joaquim Majó, Rafael Esteban.   

Abstract

This paper describes the case of a patient with HCV, without previous evidence of nephropathy, who following two well-tolerated cycles of treatment with interferon alone developed nephrotic syndrome after a third attempt with ribavirin associated with peginterferon alfa 2b. The patient exhibited a total remission when the antiviral treatment was discontinued.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 17987400     DOI： 10.1007/s11255-007-9241-7

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


  15 in total

Review 1.  Drug-induced glomerulopathies.

Authors:  Hassan Izzedine; Vincent Launay-Vacher; Edward Bourry; Isabelle Brocheriou; Svetlana Karie; Gilbert Deray
Journal:  Expert Opin Drug Saf       Date:  2006-01       Impact factor: 4.250

2.  Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit.

Authors:  Adrian Covic; Irinel-Doina Maftei; Nicoleta G I Mardare; Florentina Ioniţă-Radu; Camelia Totolici; Liliana Tuţă; Ovidiu Golea; Maria Covic; Carmen Volovăţ; Paul Gusbeth-Tatomir; Gabriel Mircescu
Journal:  J Nephrol       Date:  2006 Nov-Dec       Impact factor: 3.902

3.  The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.

Authors:  M J Alter; D Kruszon-Moran; O V Nainan; G M McQuillan; F Gao; L A Moyer; R A Kaslow; H S Margolis
Journal:  N Engl J Med       Date:  1999-08-19       Impact factor: 91.245

4.  Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis.

Authors:  G D'Amico
Journal:  Kidney Int       Date:  1998-08       Impact factor: 10.612

5.  Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.

Authors:  S W Schalm; B E Hansen; L Chemello; A Bellobuono; J T Brouwer; O Weiland; L Cavalletto; R Schvarcz; G Ideo; A Alberti
Journal:  J Hepatol       Date:  1997-05       Impact factor: 25.083

Review 6.  Effects of adding ribavirin to interferon to treat chronic hepatitis C infection: a systematic review and meta-analysis of randomized trials.

Authors:  Jesper Brok; Lise L Gluud; Christian Gluud
Journal:  Arch Intern Med       Date:  2005-10-24

7.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

8.  Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency.

Authors:  Annette Bruchfeld; Karin Lindahl; Lars Ståhle; Magnus Söderberg; Robert Schvarcz
Journal:  Nephrol Dial Transplant       Date:  2003-08       Impact factor: 5.992

Review 9.  Ribavirin monotherapy for chronic hepatitis C infection: a Cochrane Hepato-Biliary Group systematic review and meta-analysis of randomized trials.

Authors:  Jesper Brok; Lise L Gluud; Christian Gluud
Journal:  Am J Gastroenterol       Date:  2006-02-22       Impact factor: 10.864

Review 10.  Nephrotoxicity of interferon alfa-ribavirin therapy for chronic hepatitis C.

Authors:  Richard A Willson
Journal:  J Clin Gastroenterol       Date:  2002-07       Impact factor: 3.062
View more
  6 in total

1.  Nephrotic syndrome with pegylated interferon alfa 2a and ribavirin for a patient with chronic hepatitis C.

Authors:  Ajit Sood; Vandana Midha; Jaswinder S Sandhu; Neena Sood; Amarjit Kaur; Rasham Mittal; Sandeep Puri
Journal:  Indian J Gastroenterol       Date:  2010-06

2.  Efficacy and safety of pegylated IFN alfa 2b alone or in combination with ribavirin in thalassemia major with chronic hepatitis C.

Authors:  Ajit Sood; Praveen Sobti; Vandana Midha; Dinesh Singla; Amarjeet Kaur; Sandeep Kaushal; Neena Sood; Rasham Mittal; Sandeep Puri
Journal:  Indian J Gastroenterol       Date:  2010-05-05

3.  Treatment with IFN-{alpha}, -{beta}, or -{gamma} is associated with collapsing focal segmental glomerulosclerosis.

Authors:  Glen S Markowitz; Samih H Nasr; M Barry Stokes; Vivette D D'Agati
Journal:  Clin J Am Soc Nephrol       Date:  2010-03-04       Impact factor: 8.237

4.  Collapsing glomerulopathy as a complication of interferon therapy for hepatitis C infection.

Authors:  Sriraj Kanungo; Srinath Tamirisa; Rajalakshmi Gopalakrishnan; Luis Salinas-Madrigal; Bahar Bastani
Journal:  Int Urol Nephrol       Date:  2009-06-04       Impact factor: 2.370

Review 5.  De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis C (case study and literature review).

Authors:  Fabrizio Fabrizi; Alessio Aghemo; Gabriella Moroni; Patrizia Passerini; Roberta D'Ambrosio; Paul Martin; Piergiorgio Messa
Journal:  Dig Dis Sci       Date:  2013-12-08       Impact factor: 3.487

6.  Interferon Induced Focal Segmental Glomerulosclerosis.

Authors:  Yusuf Kayar; Nuket Bayram Kayar; Nadir Alpay; Jamshid Hamdard; Iskender Ekinci; Sebnem Emegil; Rabia Bag Soydas; Birol Baysal
Journal:  Case Rep Nephrol       Date:  2016-10-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.